Search Results - "Antón Torres, A."

Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists by Camps-Herrero, C., Paz-Ares, L., Codes, M., López-López, R., Antón-Torres, A., Gascón-Vilaplana, P., Guillem-Porta, V., Carrato, A., Cruz-Hernández, J. J., Caballero-Díaz, C., Blasco-Cordellat, A., Moreno-Nogueira, J. A., Díaz-Rubio, E.

“…Purpose The economic situation showed that the resources devoted to health spending are limited, making rationalisation of their consumption necessary. The…”
Get full text

Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer by Wuerstlein, R., Ellis, P., Montemurro, F., Antón Torres, A., Delaloge, S., Zhang, Q., Wang, X., Wang, S., Shao, Z., Li, H., Rachman, A., Vongsaisuwon, M., Liu, H., Fear, S., Peña-Murillo, C., Barrios, C.

“…KAMILLA is a single-arm safety study of trastuzumab emtansine (T-DM1) in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast…”
Get full text

Oncologist’s knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE study by López López, R., Camps Herrero, C., Khosravi-Shahi, P., Guillem Porta, V., Carrato Mena, A., Garcia-Foncillas, J., Cruz Hernández, J. J., Gascón Vilaplana, P., Antón Torres, A., Diaz-Rubio, E., Feyjoo Saus, M., Aranda Aguilar, E.

“…Purpose Breakthrough cancer pain (BTcP) has been shown to be a prevalent and poor prognostic factor for oncologic patients, which remain under diagnosed and…”
Get full text

First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN by Martínez-Jañez, N., Ezquerra, M. Bellet, Manso Sanchez, L. M., Carrasco, F. Henao, Torres, A. Anton, Morales, S., Ortega, P. Tolosa, Gil, V. L. Obadia, Sampedro, T., Conejero, R. Andrés, Calvo-Martinez, L., Galve-Calvo, E., López, R., de la Pena, F. Ayala, Lopez-Tarruella, S., de Araguiz, B. A. Hernando Fernandez, Ruiz, L. Boronat, Cardenas, T. Martos, Chacon, J. I., Antón, F. Moreno

“…Purpose To evaluate the efficacy and safety of first-line therapy with palbociclib in a Spanish cohort treated after palbociclib approval. Methods PALBOSPAIN…”
Get full text

5-Fluorouracil, folinic acid, epidoxorubicin and cisplatin (FLEP) combination chemotherapy in advanced measurable gastric cancer. A phase II trial of the Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) by Cervantes, A, Villar-Grimalt, A, Abad, A, Antón-Torres, A, Belón, J, Dorta, J, Tres, A, Camps, C, Fonseca, E, Massutí, B

“…Metastatic disease is a common problem in gastric cancer and the development of better chemotherapeutic regimens is a clear priority in gastrointestinal…”
Get more information

Impact of the 21-gene assay on treatment decisions in high-risk patients with ER-positive HER2-negative early breast cancer: Results of the KARMA Dx study by Llombart, A., Andrés, R., Anton Torres, A., Martinez, N., Rodriguez, C., Sánchez-Rovira, P., Rojas, B., Ruiz Borrego, M., Bermejo, B., Martinez de Dueñas, E.

Get full text

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: A Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study by Aranda, E., Díaz-Rubio, E., Cervantes, A., Antón-Torres, A., Carrato, A., Massutí, T., Tabernero, J. M., Sastre, J., Trés, A., Aparicio, J., López-Vega, J. M., Barneto, I., García-Conde, J.

“…Purpose The objective of this multicenter study was to compare the efficacy and toxicity profiles of a combination of 5-fluorouracil (5-FU) given by bolus…”
Get full text

The quality oncology practice initiative program: Experience in Spain by Lopez Lopez, R., Anton Torres, A., Aranda Aguilar, E., Carrato Mena, A., Constenla Figueiras, M., Cruz Hernandez, J.J., Diaz Rubio, E., Feyjoo, M., Garcia Foncillas, J., Gascon, P.N., Guillem Porta, V., Lugo Cuan, I.S., Rogado, A., Camps, C.

Get full text

Clinical practice evaluation of opioids induced constipation management in oncologic patients: The EIO-50 project by Salvador Bofill, J., Guillem Porta, V., Feyjoo, M., Anton Torres, A., Aranda Aguilar, E., Camps, C., Carrato Mena, A., Constenla Figueiras, M., Cruz Hernandez, J.J., Diaz Rubio, E., Garcia Foncillas, J., Gascon, P.N., Lopez Lopez, R., Soler, B., Escobar, Y.

Get full text

Psychological distress and health-related quality of life in women recently diagnosed with breast cancer in the Epi-GEICAM study by Fernández-De-Larrea, N., Pérez-Gómez, B., Ruiz, A., Casas, A.M., Bermejo, B., Baena-Cañada, J.M., Antolin, S., Sánchez Rovira, P., Ramos Vázquez, M., Garcia-Saénz, J.A., Anton Torres, A., Muñoz, M., Jara, C., Gil-Gil, M., Adrover, E., Oltra, A., Brunet, J., Bezares, S., Martín, M., Pollán, M.

Get full text

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication by Schneeweiss, A., Peretz-Yablonski, T., Nowecki, Z., Merot, J.-L., Pena-Murillo, C., Bachelot, T., Coudert, B., Nowecki, Z., Wardley, A., Puglisi, F., Montemurro, F., Hu, X., Gaafar, R., Li, H., Aktas, B., Tienghi, A., Miles, D., Lux, M., Menjon Beltran, S., Turner, N., Tong, Z., Boer, K., Horvath, Z., Susnjar, S., Matos, E., Garcia Estevez, L., Cruz, M., Bourgeois, H., von Schumann, R., Morales-Vásques, F., Voitko, N., Hicks, J., Barrett-Lee, P., Wheatley, D., Gozy, M., Latini, L., Barnadas Molins, A., Bratos, R., McCarthy, N., Kee, D., Artignan, X., Azribi, F., Jaafar, H., Augereau, P., Müller, V., Evron, E., Cascinu, S., El-Saghir, N., Ghosn, M., Oosterkamp, H.M., Kukulska, M., Levitt, N., Panwar, U., Rigg, A., Fein, L., Malik, L., Singer, C., Stoeger, H., Cedeño, M., Berdah, J.-F., Goncalves, A., Orfeuvre, H., Fried, G., Moscetti, L., Siddiqi, N., Arcediano Del Amo, A., McAdam, K., Dunn, G., Taylor, W., Hegg, R., Grosjean, J., Laplaige, P., Christensen, B., Zahm, D.-M., Inbar, M., Bonetti, A., van der Velden, A., van Warmerdam, L., Viñas Vilaro, G., Bachmeier, K., Beresford, M., Joffe, J., Nobre, A., Jiang, J., Padrik, P., Dohollou, N., Prulhiere, K., Ober, A., Alabiso, O., van de Wouw, A.J., Saadein, A., Abdelhafiez, N., Abulkhair, O., Llorente Domenech, R., Gil Raga, M., Rodriguez Sanchez, C., Torrego Garcia, J., Vicente Rubio, E., Jones, A., Alonso, I.

“…The phase III CLinical Evaluation Of Pertuzumab And TRAstuzumab (CLEOPATRA) trial established the combination of pertuzumab, trastuzumab and docetaxel as…”
Get full text

123MO BARBICAN: A randomized, phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with triple-negative breast cancer by Schmid, P., Bofill, F.J. Salvador, Bermejo, B., Phillips, M., Wheatley, D., Neus, F., Schem, C., Stradella, A., Mele, M., Salgado, A. Cortes, Quiroga, V., Torres, A. Antón, Cussac, A. Llombart, Zamora, E., Viale, G., Kuemmel, S., Prendergast, A., Mousa, K., Gluz, O., Cortés, J.

Get full text

Outpatient weekly high-dose continuous-infusion 5-fluorouracil plus oral leucovorin in advanced colorectal cancer. A phase II trial by Aranda, E., Cervantes, A., Carrato, A., Fern´ndez-Martos, C., Antón-Torres, A., Massutí, T., Barneto, I., García-Conde, J., Barón, J. M, Díaz-Rubio, E.

“…Background: Background: In a previous phase I–II trial we showed that maximum tolerable dose (MTD) of 5-fluorouracil (5-FU) a weekly 48-hour continuous…”
Get full text

Retrospective study of weekly paclitaxel-cetuximab (WPC) in unselected patients (p) with recurrent/metastatic head and neck squamous cell carcinoma (RM-SCCHN) by Bernad, I. Pajares, Trufero, J. Mártinez, Urquizu, L. Calera, de Miguel, A. Cebolleo, Cid, R. Pazo, Valero, M. Lanzuela, Agsustín, M.J., Millastre, E., Lobera, C. Santander, Alejandro, M. Alvarez, Gimeno, N., Yague, M. Malo, Llorente, Y., Torres, A. Antón

Get full text

Working towards a consensus on the oncological approach of breakthrough pain: a Delphi survey of Spanish experts by Camps Herrero, Carlos, Antón Torres, Antonio, Cruz-Hernández, Juan Jesús, Carrato, Alfredo, Constenla, Manuel, Díaz-Rubio, Eduardo, Feyjoo Saus, Margarita, Garcia-Foncillas, Jesus, Gascón, Pere, Guillem, Vicente

“…There is a lack of standards for the diagnosis, assessment and management of breakthrough cancer pain (BTcP). La Fundación ECO (the Foundation for Excellence…”
Get full text

The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD) by Aranda, E, Cervantes, A, Carrato, A, Antón-Torres, A, Massutí, T, Fernández-Martos, C, Díaz-Rubio, E

“…Background In a previous phase I to II trial, we have shown that the maximum tolerable dose (MTD) of 5-Fluorouracil (5-FU) in 48-hour continuous infusion (CI)…”
Get more information

174P Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: Phase IIIb LUCY final analysis by Balmana, J., Fasching, P.A., Delaloge, S., Park, Y.H., Eisen, A., Bourgeois, H., Kemp, Z., Jankowski, T., Sohn, J., Aksoy, S., Timcheva, C.V., Park-Simon, T-W., Anton Torres, A., John, E., Baria, K., Walker, G., Gelmon, K.A.

Get full text

LBA19 Event-free survival (EFS) analysis of neoadjuvant taxane/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study by Gianni, L., Huang, C., Egle, D., Bermejo, B., Zamagni, C., Thill, M., Anton Torres, A., Bianchini, G., Sevillano Fernandez, E., Russo, S., Ciruelos, E.M., Greil, R., Semiglazov, V., Colleoni, M.A., Kelly, C.M., Mariani, G., Del Mastro, L., Spezia, R., Ali, H., Viale, G.

Get full text

First-line phase II trial of sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma unsuitable for cytokine treatment by Maroto-Rey, P., Bellmunt, J., Trigo, J. M., Guillem, V., López-Martín, J. A., Carles, J., Antón-Torres, A., Urruticoechea, L.

“…Abstract only 15640 Background: Sorafenib (BAY 43–9006) is a serine/threonine and receptor tyrosine kinase inhibitor that prevents tumor cell proliferation and…”
Get full text

Trastuzumab plus docetaxel with or without capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer: a randomised Phase II study by Wardlev, A, Anton-Torres, A, Pivot, X, Morales-Vasquez, F, Zetina, L, de Fatima Dias Gaui, M, Otero Reyes, D, Jassem, J, Button, P, Bell, R

Get full text